# Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer

> **NCT00136487** · PHASE2,PHASE3 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 85 (—)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT00136487
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 85 (—)
- **Last updated:** 2009-12-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00136487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00136487, "Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00136487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*